950210.KS
Prestige BioPharma Limited
KSC · Healthcare · Biotechnology · SG
KRW 6,470.00
−3.72%Year over year
Reported trailing growth
- Revenue
- +77.8%
- EBITDA
- —
- EBIT
- -38.2%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +435.3%
- EBITDA
- —
- EBIT
- -37.9%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026